Report Ocean has published a new report on the Narcolepsy Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers ...

Michelle Weger is an author, motivational speaker, and entrepreneur whose great dane, Quinn, has become quite the celebrity ...

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in ...

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in ...

Harmony Biosciences surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting ...

Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo ...

In September 2024, the Company presented multiple data analyses at Sleep Europe 2024, including results from the SYMPHONY ...

Sleep disorders like sleep apnea or narcolepsy can also trigger oversleeping, the NIH says. Sleep apnea, which involves a repeated stopping and starting of breathing throughout the night, is a common ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day everyone and welcome to today’s Avadel Pharmaceuticals ...

Generated $50.0 million in net revenue from sales of LUMRYZ™ ----2,300 patients on LUMRYZ as of September 30th, including 700 patients that ...

Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing innovative treatments to improve patient lives, with a particular emphasis on sleep-related disorders such as narcolepsy ...

SEC recommends approval for MSN Laboratories' sleep disorder drug: Gireesh Babu, New Delhi Saturday, November 9, 2024, 08:00 Hrs [IST] The Subject Expert Committee (SEC), which ad ...